III/IV期上皮性卵巢癌积极手术的生存与安全性:单机构观察性研究
在非高手术量中心评估III/IV期卵巢、输卵管及腹膜癌积极手术的疗效与安全性。2008年1月至2012年12月连续106例患者中87例(82%)按方案接受积极手术,中位无进展生存期从实施前的14.6个月增至25.0个月,中位总生存期从38.1个月增至68.5个月;完全切除83例(78%),术后12周内无死亡,8例发生主要并发症。
要点
- 实施积极手术方案后,中位无进展生存期由14.6个月升至25.0个月,中位总生存期由38.1个月升至68.5个月。
- 106例中83例(78%)实现完全切除,61例(58%)手术复杂度评分>8。
- 术后12周内无死亡,8例发生主要并发症。
核心结论
- 在非高手术量中心实施晚期卵巢癌积极手术后结局改善,且未导致死亡率显著增加。
研究设计与样本
- 单机构观察性研究,纳入2008年1月至2012年12月连续106例III/IV期卵巢、输卵管及腹膜癌接受择期积极手术的患者,并与2000年至2007年接受标准手术的患者比较。
- 妇科手术团队经9个月培训后开始行多脏器切除术;初次肿瘤细胞减灭术在初次剖腹探查认为可达到满意手术时选择,否则选择间歇性肿瘤细胞减灭术。
- 分析基于意向性治疗(全分析集),106例中87例(82%)按方案接受积极手术,19例被排除。
主要发现
- 浆液性癌最常见(78%),其次为透明细胞癌(7%),32%的患者为IV期。
- 中位无进展生存期从实施前的14.6个月增至实施后的25.0个月,中位总生存期从38.1个月增至68.5个月。
- 106例中83例(78%)实现完全切除,61例(58%)手术复杂度评分>8。
- 术后12周内无死亡,8例发生主要并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the efficacy and safety of aggressive surgery for advanced ovarian cancer at a non-high-volume center. MATERIALS AND METHODS: We evaluated consecutive patients with stage III/IV ovarian, fallopian, and peritoneal cancer undergoing elective aggressive surgery from January 2008 to December 2012, which encompassed the first 5years after implementing an aggressive surgery protocol. After receiving appropriate training for 9months, a gynecological surgical team began performing multi-visceral resections. Primary debulking surgery was chosen when the team considered that optimal surgery was achievable on the initial laparotomy, otherwise interval debulking surgery was chosen (the protocol treatments). Analysis was performed on an intention-to-treat basis (full-set analysis), and outcomes were compared to those of patients who underwent standard surgery between 2000 and 2007. RESULTS: Of 106 consecutive patients studied, 87 (82%) underwent aggressive surgery per protocol and 19 were excluded. Serous carcinoma was the most common disease (78%), followed by clear cell carcinoma (7%), and 32% of the patients had stage IV disease. The respective median progression-free and overall survival rates increased from 14.6 and 38.1months before implementation, respectively, to 25.0 and 68.5months after implementation, respectively. Complete resection was achieved in 83 of the 106 patients (78%), and the surgical complexity score was high (>8) in 61 patients (58%); although there was no mortality within 12weeks of surgery, major complications occurred in 8 patients. CONCLUSIONS: We confirmed that outcomes improved after implementing aggressive surgery for advanced ovarian cancer, without causing a significant increase in mortality. Factors enhancing survival outcomes are discussed.
引用
- Tate S, Kato K, Nishikimi K, et al. Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study. Gynecol Oncol. 2017. PMID: 28800941. doi:10.1016/j.ygyno.2017.07.136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。